Houston Chronicle

Shot drive enters newphase as global vaccine efforts intensify

- By Eugene Garcia and Danica Kirka

The first Americans inoculated against COVID-19 began rolling up their sleeves for their second and final dose Monday, while Britain introduced another vaccine on the same day it imposed a newnationw­ide lockdown against the rapidly surging virus.

New York State, meanwhile, announced its first known case of the newand seeminglym­ore contagious variant, detected in aman in his 60s in Saratoga Springs. Colorado, California and Florida previously reported infections involving the mutant version that has been circulatin­g in England.

The emergence of the variant has added even more urgency to the worldwide race to vaccinate people against the scourge.

In Southern California, intensive care nurseHelen Cordova got her second dose of the Pfizer vaccine at Kaiser Permanente Los Angeles Medical Center along with other doctors and nurses, who bared their arms the prescribed three weeks after they received their first shot. The second round of shots began in various locations around the country as the U.S. death toll surpassed 352,000.

“I’m really excited because that means I’m just that much closer to having the immunity and being a little safer when I come to work and, you know, just being around my family,” Cordova said.

Over theweekend, U.S. government officials reported that vaccinatio­ns had accelerate­d significan­tly. As of Monday, the Centers for Disease Control and Prevention said nearly 4.6 million shots hadbeen dispensed in the U.S., after a slow and uneven start to the campaign, marked by confusion, logistical hurdles and a patchwork of approaches by state and local authoritie­s.

Britain, meanwhile, became the first nation to start using the COVID-19 vaccine developed by Astra Zeneca and Oxford University, ramping up its nationwide inoculatio­n campaign amid soaring infection rates blamed on thenew variant. Britain’s vaccinatio­n program began Dec. 8 with the shot developed by Pfizer and its German partner BioNTech.

Brian Pinker, an 82-year-old dialysis patient, received the first Oxford-Astra Zenec as hot at Oxford University Hospital, saying in a statement: “I can now really look forward to celebratin­g my 48th wedding anniversar­y.“

New lockdown in England

The rollout came the same day Prime Minister Boris Johnson announced a new lockdown for England until at least mid-February. Britain has recorded more than 50,000 new coronaviru­s infections a day over the past six days, and deaths have climbed past 75,000, one of the worst tolls in Europe.

Schools and colleges will generally be closed for face-to-face instructio­n. Nonessenti­al stores and services like hairdresse­rs will be shut down, and restaurant­s can offer only takeout.

“As I speak to you tonight, our hospitals are under more pressure from COVID than at any time since the start of the pandemic,”

Johnson said.

Elsewhere around the world, France and other parts of Europe have come under fire over slow vaccine rollouts and delays.

France’s cautious approach appears to have backfired, leaving just a few hundred people vaccinated after the first week and rekindling anger over the government’s handling of the pandemic. The slow rollout has been blamed on mismanagem­ent, staffing shortages over the holidays and a complex consent policy designed to accommodat­e vaccine skepticism among the French.

“It’s a state scandal,” Jean Rottner, president of the Grandest region of eastern France, said on France-2 television. “Getting vaccinated is becoming more complicate­d than buying a car.“

French media broadcast charts comparing vaccine figures in various countries: In France, a nation of 67 million people, just 516 people were vaccinated in the first six days, according to the French Health Ministry. Germany’s firstweek total surpassed 200,000, and Italy’s was over 100,000. Millions have been vaccinated in the U.S. and China.

The European Union likewise faced growing criticism about the slow rollout of COVID-19 shots across the 27-nation bloc of 450 million inhabitant­s. EU Commission spokesman Eric Mamer said the main problem “is an issue of production capacity, an issue that everybody is facing.”

The EU has sealed six vaccine contracts with a variety of manufactur­ers. But only the PfizerBioN­Tech vaccine has been approved for use so far across the

EU. The EU’s drug regulators are expected to decide on Wednesday whether to recommend authorizin­g the Moderna vaccine.

Demand lower at some sites

In the U.S., Dr. Mysheika Roberts, health commission­er in Columbus, Ohio, said demand has been lower than expected among the people given top priority for the vaccine. For example, the city’s 2,000 emergency medical workers are all eligible, but the health department has vaccinated only 850 of them.

She said some peoplewere hesitant to get the vaccine and wanted to see how others handled it. The vaccine also arrived theweek of Christmas, and a lot of people were on vacation and didn’t want to be bothered, she said.

“I think we all assumed that people would want this vaccine so badly, that when it became available, peoplewoul­d just come get it,” Roberts said.

Elsewhere aroundthe globe, Israel appears to be among the world leaders in the vaccinatio­n campaign, inoculatin­g over 1 million people, or roughly 12 percent of its population, in just over two weeks.

On Sunday, India, the world’s second-most populous country, authorized its first two COVID-19 vaccines — the Oxford-AstraZenec­a one and another developed by an Indian company. The move paves the way for a huge inoculatio­n program in the desperatel­y poor nation of 1.4 billion people.

India has confirmed more than 10.3 million cases, second in the world behind the U.S. It also has reported about 150,000 deaths.

 ?? Paul Ellis / AFP via Getty Images ?? Naomi Carpenter, a 20-year-old sports rehab student at Hull University in England, takes a swab for a COVID-19 test. Britain, one of the worst-affected countries by the global health crisis, is pinning its hopes on its mass vaccinatio­n drive.
Paul Ellis / AFP via Getty Images Naomi Carpenter, a 20-year-old sports rehab student at Hull University in England, takes a swab for a COVID-19 test. Britain, one of the worst-affected countries by the global health crisis, is pinning its hopes on its mass vaccinatio­n drive.

Newspapers in English

Newspapers from United States